The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.

scientific article published on 28 June 2018

The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. is …
instance of (P31):
scholarly articleQ13442814

External links are
P5530Altmetric DOI10.1186/S12874-018-0509-7
P6409CORE ID160500318
P6179Dimensions Publication ID1105178437
P356DOI10.1186/S12874-018-0509-7
P953full work available at URLhttp://eprints.whiterose.ac.uk/134842
P932PMC publication ID6022299
P698PubMed publication ID29954322
P1154Scopus EID2-s2.0-85049153640

P50authorMichael O'DwyerQ56447633
Susanne SchmitzQ61846032
P2093author name stringJames Morris
Ayesha Khan
Jack Bowden
Gordon Cook
Cathal Walsh
Isla Kuhn
Kai Ruggeri
Áine Maguire
Vanessa Buchanan
Elisa Haller
Joy Leahy
Natalia Homer
P2860cites workCurrent and emerging treatment options for patients with relapsed myelomaQ26830878
Combination of direct and indirect evidence in mixed treatment comparisonsQ29619499
Incorporating data from various trial designs into a mixed treatment comparison modelQ30594247
Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertensionQ30936117
Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myelomaQ33375404
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionQ33376149
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaQ33377526
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).Q33391803
Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomideQ33399196
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 RQ33401216
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trialQ33408494
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Q33409172
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaQ57904272
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaQ60997833
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myelomaQ80332885
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse eventsQ84519502
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myelomaQ84587252
Multiple myelomaQ86407303
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patientsQ89777946
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaQ33409825
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialQ33410172
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyQ33410481
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.Q33415539
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myelomaQ33416418
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialQ33417762
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyQ33428423
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaQ33434817
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaQ33435789
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyQ33942495
Mixed treatment comparisons using aggregate and individual participant level dataQ34327201
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaQ34585268
Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysisQ35104606
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trialQ35930659
Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities.Q36253136
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyQ36382493
The treatment of relapsed and refractory multiple myelomaQ37007400
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myelomaQ37219701
Treatment of multiple myeloma: a comprehensive reviewQ37542173
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyQ37655019
Emerging therapies for the treatment of relapsed or refractory multiple myelomaQ37799862
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.Q38637962
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple MyelomaQ38939812
Systematic Review and Network Meta-Analysis of Treatment Outcomes for Multiple MyelomaQ39430600
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupQ39605645
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.Q40392114
Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screeningQ40734392
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaQ41700620
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use programQ43108154
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasoneQ43195076
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchQ43993739
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialQ44735204
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaQ46549268
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratioQ46634193
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centersQ46902812
A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidenceQ47626233
Endovascular Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of Current TechnologiesQ47794965
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanerceptQ50129900
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P304page(s)66
P577publication date2018-06-28
P1433published inBMC Medical Research MethodologyQ15752152
P1476titleThe use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.
P478volume18

Reverse relations

Q64074928Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysiscites workP2860

Search more.